Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
Dialysis Unit, Regional Specialist Hospital, Radom, Poland.
Bone. 2020 Apr;133:115188. doi: 10.1016/j.bone.2019.115188. Epub 2019 Dec 13.
The usefulness of FRAX in predicting major bone fractures in patients with end-stage kidney disease on maintenance hemodialysis treatment has been confirmed in previous studies. For meaningful clinical use, the prognostic and intervention FRAX thresholds need to be established.
The primary aim of our study was to calculate the optimal cut-off point of FRAX for the best prediction of an increased bone fracture risk in dialysis patients and additionally, to propose its intervention threshold, indicating the need for antifracture pharmacological treatment. The study included 718 hemodialysis patients, who were followed up for two years. Thirty low-energy major bone fractures were diagnosed during the study period. We used the Polish version of FRAX (without the DXA examination) and some particular variables of the FRAX calculator. The optimal cut-off point for prediction of an increased major bone fracture risk was based on the analysis of the sensitivity and specificity curves of FRAX.
The analysis revealed FRAX >5% (sensitivity of 70.0%, specificity of 69.8%) as the prognostic threshold for major bone fractures. Its sensitivity for bone fracture prediction was significantly higher, but specificity lower than those of FRAX ≥10%, used in general Polish population. The reason for this can be an underestimation of bone fracture risk with FRAX in dialysis patients.
We conclude that the FRAX prognostic threshold for identification of an increased risk of major bone fractures in hemodialysis patients is >5%. We propose to use this specific value of FRAX as an intervention threshold for pharmacological antifracture treatment in hemodialysis patients.
先前的研究已经证实,FRAX 在预测接受维持性血液透析治疗的终末期肾病患者的主要骨折方面具有一定的作用。为了实现有意义的临床应用,需要确定预测骨折的预后和干预 FRAX 阈值。
本研究的主要目的是计算 FRAX 最佳截断值,以更好地预测透析患者的骨折风险增加,并提出其干预阈值,提示需要进行抗骨折药物治疗。研究纳入了 718 名血液透析患者,对其进行了为期两年的随访。研究期间共诊断出 30 例低能量主要骨折。我们使用了波兰版 FRAX(不包括 DXA 检查)和 FRAX 计算器的一些特定变量。最佳截断值是基于 FRAX 曲线的敏感性和特异性分析得出的。
分析显示,FRAX>5%(敏感性为 70.0%,特异性为 69.8%)是预测主要骨折风险的预后阈值。与在一般波兰人群中使用的 FRAX≥10%相比,FRAX 预测骨折的敏感性显著更高,但特异性更低。这可能是由于 FRAX 在透析患者中低估了骨折风险。
我们得出结论,FRAX 预测血液透析患者主要骨折风险增加的预后阈值为>5%。我们建议将 FRAX 的这一特定值用作血液透析患者药物抗骨折治疗的干预阈值。